Cryo-Cell International, Inc. (CCEL) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended February 28, 2025. Cryo-Cell International, Inc. is a smaller reporting company organized into three segments: (1) cellular processing and cryogenic storage of umbilical cord blood and tissue for family use; (2) manufacture of PrepaCyte CB units; and (3) cryogenic storage of cord blood for public use. The company operates primarily from facilities in Oldsmar, Florida, and Durham, North Carolina.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $7,968,880 | $7,852,235 |
| Net Income | $282,855 | $556,241 |
| Operating Income | $1,056,011 | $821,223 |
| Net Cash from Operating Activities | $954,063 | ($356,865) |
| Cash and Cash Equivalents (End of Period) | $223,122 | $247,112 |
| Total Debt (Current + Long-Term) | $13,022,901 | $12,000,521 |
| Stockholders' Deficit | ($14,656,309) | ($10,338,012) |
Note: Total Debt includes a $4,570,000 line of credit and a net note payable of $8,451,901. The company maintains a significant deferred revenue balance of $57,173,343.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 1.5% year-over-year, driven by a 4% increase in recurring annual storage fees and a 88% increase in public banking revenue. This was partially offset by a 12% decrease in new domestic cord blood specimens processed.
- Profitability Decline: Net income decreased 49% to $282,855, primarily due to a $266,000 increase in interest expense and a $306,000 swing in other income/expense (losses on marketable securities vs. prior year gains).
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 5% to $4.64 million. Depreciation and amortization increased significantly to $191,853 (from $33,186) due to the new Durham, NC facility.
- Dividend Payment: The company paid a cash dividend of $0.25 per share ($2.02 million total) in Q1 2025, compared to no dividend in Q1 2024.
- Debt Utilization: The revolving line of credit balance increased from $3.52 million to $4.57 million.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management states that cash flows from operations, marketable securities, and external capital sources are sufficient to fund known needs for the next 12 months. However, future funding needs related to the Duke License Agreement are currently unpredictable due to ongoing arbitration. The company does not anticipate further investments in Duke-related activities (other than a comparability study under $350,000) until the dispute is resolved. The opening of the Cryo-Cell Institute for Cellular Therapies and the proposed spinoff of Celle Corp. are on hold pending the outcome of the Duke arbitration.
Material Risks and Contingencies:
- Duke University Arbitration: The company filed a demand for arbitration against Duke University alleging fraudulent inducement and breach of contract regarding the Duke License Agreement, seeking damages in excess of $100 million. Duke has filed counterclaims. The outcome is uncertain and could materially impact the company's ability to commercialize licensed rights or proceed with the Celle Corp. spinoff.
- Legal Proceedings: A class action lawsuit regarding advertising claims (Lindsey Lehr v. Cryo-Cell) was converted to individual arbitration, with a final hearing scheduled for September 2025.
- Liquidity: While currently sufficient, the company may require additional debt or equity financing if revenue growth stalls or if the Duke dispute resolution requires significant capital.
Investor Verification Checklist
- Duke Arbitration Status: Verify the current status of the arbitration demand against Duke University and the potential impact on the $13.1 million previously impaired asset and future revenue streams.
- Debt Covenants: Confirm compliance with the Susser Bank credit agreement covenants, specifically the Leverage Ratio (max 3.50:1) and Debt Service Coverage Ratio (min 1.25:1).
- Deferred Revenue Recognition: Review the $57.2 million deferred revenue balance to understand the timing of future revenue recognition and the stability of the customer base.
- Dividend Sustainability: Assess the sustainability of the $0.25/share dividend given the stockholders' deficit and the cash outflow of $2.02 million in a single quarter.
- Public Banking Inventory: Verify the valuation and sell-through rate of the public cord blood inventory ($5.2 million) stored at Duke, given the ongoing dispute.